Amgen's migraine drug succeeds in late-stage trial
- Major stock indexes rise again to new records
- Unusual 11 Mid-Day Movers 12/8: (COOL) (TLRD) (DRAM) Higher; (SHIP) (OHRP) (MLSS) Lower
- Third-Party Said Interested in PrivateBancorp (PVTB) as CIBC (CM) Deal is Delayed
- Insys Therapeutics (INSY) Sinks as Former Employees Arrested in Racketeering Scheme
- Lower for longer, ECB scales back asset buys
An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
(Reuters) - Amgen Inc (NASDAQ: AMGN) said on Wednesday its migraine treatment met the main goal of reducing monthly migraine days in patients with episodic migraine in a second late-stage study.
Patients receiving 70 milligram of the drug, erenumab, experienced reduction of 3.2 days from baseline in monthly migraine days, while those on 140 milligram experienced reduction of 3.7 days. Those in the placebo experienced a 1.8-day reduction, the company said.
At baseline, patients were experiencing an average of 8.3 migraine days per month, Amgen said.
Amgen, which is co-developing the treatment with Swiss drugmaker Novartis AG (NASDAQ: NOVN), said patients received the injectable drug once monthly for six months.
Erenumab is also being tested for episodic migraine prevention and chronic migraine prevention.
Worldwide, about 90 percent of people diagnosed with migraine have episodic migraine, which is characterized by up to 14 migraine days a month, the company said.
Amgen's shares, which closed at $147.23 in regular trading, were up marginally after market on Wednesday.
(Reporting by Divya Grover in Bengaluru)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ex-JPMorgan employee accused of $5 million scheme to defraud bank
- German move on new ship radars paves way for missile defense role
- Brazilian squatters offer shelter from anti-gay violence
Create E-mail Alert Related CategoriesFDA, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!